BP Ventures

New Science Ventures (NSV), founded in 2004, is a venture capital firm that focuses on investments in life sciences and information technology. With offices in New York and London, NSV aims to leverage breakthrough science to create significant value. The firm has a diverse portfolio, investing in companies that utilize fundamental, science-based innovations to address large unmet needs. NSV's notable investments include Ventyx Biosciences, which raised $114 million to advance its pipeline of immunology programs, and Paragraf, a company that mass-produces graphene electronics. Other significant portfolio companies are Phase Four, which develops next-generation electric propulsion solutions for satellites, and NorthSea Therapeutics, which focuses on novel treatments for liver-related diseases​. The firm typically invests in early to mid-stage companies and supports them through crucial value inflection points to help them scale. Their investment strategy is grounded in strong intellectual property protection and a long-term view​.